HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Aurobindo Pharma’s arm gets US FTC’s nod for acquiring 100% of membership interest in Lannett
Jun-19-2026

Aurobindo Pharma’s wholly owned subsidiary -- Aurobindo Pharma USA Inc. has received the necessary approval from US Federal Trade Commission (FTC) for the acquisition of the 100% of membership interest in Lannett Company LLC (Lannett) from Lannett Seller Holdco, Inc.

Earlier, Aurobindo Pharma USA Inc had entered into a definitive agreement with Lannett Seller Holdco Inc for the same. The transaction aligns with the company’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities.

Through this acquisition, the company will gain access to: a complementary portfolio of profitable products, a growing Contract Development and Manufacturing Organization (CDMO) business, and a U.S.-based manufacturing facility with significant excess capacity (425k sq. ft facility with around 3.6bn doses capacity) and with potential for further expansion. The cost of said acquisition is based on an enterprise value of $250 million (Rs 2185 crore) on a cash free debt free basis and including normalized levels of working capital.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

  RELATED NEWS >>